Investors Count
1Deal Terms
1Nimbus Therapeutics - Nimbus Therapeutic and Acetyl-CoA Carboxylase (ACC) Inhibitor Program Funding, Nimbus Therapeutics - Nimbus Therapeutic and Acetyl-CoA Carboxylase (ACC) Inhibitor Program Valuation & Nimbus Therapeutics - Nimbus Therapeutic and Acetyl-CoA Carboxylase (ACC) Inhibitor Program Revenue
1 Fundings
Nimbus Therapeutics - Nimbus Therapeutic and Acetyl-CoA Carboxylase (ACC) Inhibitor Program's latest funding round was a Acquired Unit for on April 6, 2016.
Nimbus Therapeutics - Nimbus Therapeutic and Acetyl-CoA Carboxylase (ACC) Inhibitor Program's latest post-money valuation is from April 2016.
Sign up for a free trial to see Nimbus Therapeutics - Nimbus Therapeutic and Acetyl-CoA Carboxylase (ACC) Inhibitor Program's valuations in April 2016 and more.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
4/6/2016 | Acquired Unit | 3 |
Date | 4/6/2016 |
|---|---|
Round | Acquired Unit |
Amount | |
Investors | |
Valuation | |
Revenue | |
Sources | 3 |
Nimbus Therapeutics - Nimbus Therapeutic and Acetyl-CoA Carboxylase (ACC) Inhibitor Program Deal Terms
1 Deal Term
Nimbus Therapeutics - Nimbus Therapeutic and Acetyl-CoA Carboxylase (ACC) Inhibitor Program's deal structure is available for 1 funding round, including their Acquired Unit from April 06, 2016.
Round | Acquired Unit |
|---|---|
Funding Date | |
Pre-Money Valuation | |
Post-Money Valuation | |
Amount Raised | |
Shares Authorized | |
Issuance Price | |
Dividend Rate | |
Liquidation Preferences | |
Liquidation Price | |
Participation | |
Conversion Price | |
Anti Dilution | |
General Voting | |
Board Voting | |
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Acquired Unit |
Nimbus Therapeutics - Nimbus Therapeutic and Acetyl-CoA Carboxylase (ACC) Inhibitor Program Investors
1 Investors
Nimbus Therapeutics - Nimbus Therapeutic and Acetyl-CoA Carboxylase (ACC) Inhibitor Program has 1 investors. Gilead Sciences invested in Nimbus Therapeutics - Nimbus Therapeutic and Acetyl-CoA Carboxylase (ACC) Inhibitor Program's Acquired Unit funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
4/6/2016 | 4/6/2016 | 1 Acquired Unit | Corporation | California |
First funding | 4/6/2016 |
|---|---|
Last Funding | 4/6/2016 |
Investor | |
Rounds | 1 Acquired Unit |
Board Seats | |
Type | Corporation |
Location | California |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.